Business Context and Reporting Period
This Form 8-K is a Current Report filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on October 20, 2025. The registrant is a Delaware corporation with its principal executive office in Cambridge, MA, and its common stock trades on the NASDAQ Capital Market under the symbol LPTX. The filing reports on Item 8.01 (Other Events) regarding the announcement of final clinical study results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development milestone and does not contain financial statements or quantitative financial data.
Material Changes
The material event reported is the issuance of a press release on October 20, 2025, announcing the final results from Part B of the DeFianCe study. These results were presented by Zev Wainberg, MD, at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. No financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the presentation of the DeFianCe study results. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the standard disclosure of the clinical event. The press release detailing the results is filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the specific clinical outcomes and statistical significance of the DeFianCe study Part B results in the attached press release (Exhibit 99.1).
- Confirm the regulatory implications of these results for the Company's drug candidates.
- Review the Company's most recent 10-Q or 10-K for current financial health, cash runway, and debt obligations, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on regulatory submissions or partnership discussions triggered by these results.